The US Food and Drug Administration (FDA) has cleared Roche’s wireless hospital blood glucose monitoring system for managing diabetes.
Using new patented technology, the point-of-care ACCU-CHEK Inform II measures a 0.6µl capillary blood sample and provides results in just five seconds.
The technology also allows the metre and test strip to provide accurate test results with no interference limitation from maltose, xylose or oxygen.
The system, which includes a durable design to meet stringent new cleaning and disinfecting guidelines, features unique patient identifiers that enable hospital healthcare professionals to improve the patient identification accuracy.
The system also enables automatic real-time wireless transfer of patient data between hospital medical staff and laboratory.
Roche Diagnostics chief operating officer Roland Diggelmann said accuracy and patient safety are important concerns for blood glucose testing in point-of-care settings such as hospitals.
"ACCU-CHEK systems have been proven in hospitals around the world and this next-generation wireless system sets a new standard by offering US healthcare professionals new capabilities to help ensure the accuracy of test results, streamline data communications and provide optimal patient care," Diggelmann said.
It is estimated that a total of 25.8 million US adults and children suffered from diabetes in 2011, according to the company.
Image: Roche headquarters in Basel, Switzerland. Photo: Courtesy of F Hoffmann-La Roche Ltd.
